Skip to main content

Talk Bio

Search This Blog

Otsuka's $1.225B Acquisition of Transcend Therapeutics for PTSD Neuroplastogen TSND-201

on March 31, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Otsuka Pharmaceutical agreed to acquire Transcend Therapeutics for $700 million upfront plus up to $525 million in milestones, totaling $1.225 billion.1 2 3 4 5 6

The deal targets Transcend's lead asset TSND-201, a non-hallucinogenic MDMA analog and neuroplastogen for PTSD with FDA Breakthrough Therapy designation, positive phase 2 data published in JAMA Psychiatry in February 2026, and ongoing phase 3 recruitment.1 3

Acquisition expected to close in Q2 2026, subject to customary conditions, expanding Otsuka's psychiatric and neurological portfolio.1 2 3 7 8

Transcend, founded in 2021 in New York, focuses on rapid-acting neuropsychiatric treatments inducing neural plasticity.1 3 4

Sources:

1. https://www.fiercebiotech.com/biotech/otsuka-picks-transcend-1225b-acquisition-highlighting-mdma-analog

2. https://www.otsuka-us.com/news/otsuka-pharmaceutical-acquire-transcend-therapeutics-expands-otsuka-portfolio-psychiatric-and

3. https://www.otsuka.co.jp/en/company/newsreleases/2026/20260327_2.html

4. https://www.goodwinlaw.com/en/news-and-events/news/2026/03/announcements-lifesciences-goodwin-advises-transcend-therapeutics

5. https://www.biopharmaboardroom.com/news/44/4527/otsuka-pharmaceutical-co-ltd-to-acquire-transcend-therapeutics-inc-in-1-2-billion-deal-to-advance-next-generation-ptsd-therapies.html

6. https://firstwordpharma.com/story/7150126

7. https://trial.medpath.com/news/60f7bff64e59dae7/otsuka-acquires-transcend-therapeutics-for-1-2-billion-to-advance-ptsd-treatment-with-breakthrough-therapy-tsnd-201

8. https://www.biospectrumasia.com/news/41/27430/japans-otsuka-pharma-buys-transcend-therapeutics-for-1-2-b.html

acquisition Midomafetamine Otsuka Post-Traumatic Stress Disorder Transcend Therapeutics TSND-201

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Xaira Therapeutics Launches X-Cell: First AI Virtual Cell Model Testing Scaling Laws on Massive Perturbation Data

Xaira Therapeutics announced X-Cell on March 17, 2026, a 4.9-billion-parameter diffusion language model, the largest virtual cell model to date, trained on X-Atlas/Pisces, the largest genome-wide CRISPRi Perturb-seq dataset with 25.6 million perturbed single-cell transcriptomes across seven diverse contexts. 1 2 X-Cell predicts cell responses to genetic perturbations, outperforming existing models by up to five-fold on metrics like Pearson delta, and generalizes zero-shot to unseen biological contexts such as iPSC-derived melanocyte progenitors and primary human CD4+ T cells. 1 2 The model follows power-law scaling dynamics similar to large language models, using a novel diffusion architecture that iteratively refines predictions. 2 Xaira, founded in 2024 with over $1 billion funding, plans to expand X-Atlas to primary cells, organoids, and in vivo perturbations, focusing on inflammatory/immunological diseases and antibody therapeutics. 1 3 A subset of the Pisces dataset and X-...

Isomorphic Labs Claims Major Advance with IsoDDE, Surpassing AlphaFold 3 in AI Drug Design

Isomorphic Labs unveiled the Isomorphic Labs Drug Design Engine (IsoDDE), claiming it more than doubles AlphaFold 3's accuracy on challenging protein-ligand structure prediction benchmarks for structures dissimilar to training data 1 2 . IsoDDE predicts small molecule binding affinities exceeding gold-standard physics-based methods at a fraction of the time and cost, and identifies novel binding pockets using only protein sequences in seconds 1 2 . The system achieves step-change generalization, particularly on difficult antibody regions like CDR-H3 loops, and is used daily in Isomorphic Labs' research programs 2 . Isomorphic Labs announced a research collaboration with Johnson & Johnson on January 20, 2026, leveraging IsoDDE for multi-modality drug discovery including small molecules and biologics 3 4 5 . IsoDDE technical details are in the company's report, building on AlphaFold 3 released in 2024 2 . Sources: 1. https://the-decoder.com/googles-ai-drug-dis...

Powered by Blogger

X-Data LLC